Surgical treatment of morbid obesity is warranted since it will treat or prevent many of the obesity related co-morbidities. However, there are only a few prospective studies to prove that. The meta-analysis by Henry Buchwald does provide quite convincing evidence to prove that surgically induced weight loss positively affects the obesity related co-morbidity. Co-morbidities such as diabetes mellitus (86% improved or cured), hypertension (78.5%), sleep apnea (85.7%) and hyperlipedemia (>70%) are very significantly improved. Although truly randomized trials are scarce and long term follow up is still lacking, the overall results are very impressive and according to the study of Sampalis and Christou cost effective. The only study that has reported data with a prospective follow up of more than 10 years is the Swedish Obese Subject (SOS) study. Even with a suboptimal setup of the study (patients were not randomized but choose the type of surgery themselves) the results are good in particular for type II diabetes. To further underline the positive role of surgically induced weight loss on obesity related comorbidities, basic research is mandatory. In the past decades a number of groups have studied the effects of weight loss on cytokines and in particular adipokines. Several researchers have shown the relation of cytokines with most of the known obesity related morbidities. For example a significant relation was shown between C-reactive Protein (CRP) and cardiovascular disease and of Tumor Necrosis Factor (TNFα) and type II diabetes. On the other hand several studies have shown a clear relation of increasing adiposity and increasing inflammatory mediators in these patients. Extrapolation of these findings suggests that increased inflammatory mediators are thus responsible for (or at least related to) the presence of co-morbidities(10). This would also implicate that if surgically induced weight loss is associated with a reduction of the inflammatory mediators, this could be further prove of the positive effect of surgical treatment on the comorbidities related to obesity. In recent years adipose tissue, initially only considered as an energy store, has been recognized to be actively involved in many of the complex mechanisms of energy homeostasis. An increasing number of so called adipokines have been reported that all have important roles in the regulation of satiety, insulin sensitivity and cytokine release. These adipokines include, Adiponectin, Leptin, Resistin, Visvatin but also a number of known cytokines such as Interleukin 6 (IL-6), Tumor Necrosis Factor (TNFα), Macrophage migration Inhibiting Factor (MIF), IL-8, IL-10 and IL-1. It has become clear that increasing overweight results in dysregulation of these adipokines which may cause deterioration of obesity related co-morbidities. In fact some authors have referred to obesity as an endocrine tumor. The goal of surgery is reduction or prevention of risk on co-morbidities and of course weight loss. An important question is whether a mere reduction of fat mass is sufficient or whether it is the whole picture of reduced food intake and the resulting weight loss. In a very nice experiment Klein and colleagues showed that a significant reduction of fat mass by liposuction did not result in improvement of co-morbidities. As stated before a number of studies have reported on high levels of inflammatory mediators in morbidly obese patients. If surgically induced weight loss does result is a decrease of these inflammatory mediators this may indicate that the morbidities will improve as well. At this moment there are a number of studies that have shown that the inflammatory mediators do improve significantly. After restrictive surgery we found that most pro-inflammatory mediators including CRP, IL-6, LBP, AGP, Leptin and soluable TNFR 55 improved rapidly to reach near normal values after one to two years. Parallel to that we found a significantly improved insulin sensitivity (unpublished data). Similarly mediators related to cardiovascular disease such as the endothelial activation markers soluable ICAM-1, sE-selectin, sVCAM-1, PAI-1 and regulators of endothelial activation: adiponectin, resistin and CRP improved significantly after surgically induced weight loss. And this is also true for the adipokines that are strongly related to food homeostasis such as leptin, ghrelin, orexin and cholecystokinin. These adipokines are not only important in regulation of satiety but some, such as leptin are part of the complex cytokine network. Leptin is considered an anti inflammatory mediator playing an important role in balancing the inflammatory respons following a trauma or infection. It is obvious that in the morbidly obese patients the dysbalance of the cytokine network can have severe implications. The effect of surgically induced weight loss does provide indirect evidence that indeed the obesity related morbidity can be treated and or prevented. Improvement of the mediators related to Diabetes Mellitus and atherosclerosis and the often strong improvement of the lipid metabolism does support the positive effect of significant weight loss. Whether the type of surgery makes a difference is a question not yet answered but apparently bypass surgery has a better effect on glucose intolerance and DM. And the most drastic type of bypass surgery the biliopancreatic diversion has an impressive effect on the lipid profile even in genetic lipid disorder syndromes. So maybe surgery not only induces weight loss by reducing energy intake and/or energy absorption but also has a positive influence on several gut hormones and consequently many of the now known adipokines. In conclusion the bariatric surgery really is an endocrine or better metabolic surgeon. He or she does treat the endocrine tumor that is the result of the a combination of excess energy intake, genetic disposition and environmental changes causing a massive storage of energy in the adipocytes. Many of the phenomena observed are probably an attempt to protect the body from the bad effect of this energy surplus, causing only further deterioration. Control of this problem fortunately can be obtained and does result in significant improvement of health in general.
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Restrictive procedures in bariatric surgery Gastric restrictive procedures (RP), or so called food limitation operations, are being used in the treatment of morbid obesity since the early seventies of the last century. RP mechanically limit (restrict) amount of food the patient able to eat at a time. Restrictive procedures (especially the adjustable gastric banding -AGB), are low risk, relatively easy to perform, anatomically reversible, short-term hospitalization surgeries. Nowadays, there are several restrictive procedures being used: the most common is AGB, and / or gastric bypass (RYGBP -proximal or long-limb). Vertical banded gastroplasty (VBG), which was very popular in the past decades, has became massively abandoned. Gastric sleeve resection is being used in some centres, however long-term efficacy data of this operation are still missing. The two most commonly performed restrictions, the AGB and RYGBP have substantially different penetration patterns in the USA and in Europe. In the USA the RYGBP is more frequent, whereas AGB is more prevalent in Europe. Although there is a noticeable tendency to increase AGB in the USA, and vice-versa, the RYGB in Europe. Regardless differences in weight loss, surgical morbidity (even though extremely low) and requirements on postoperative follow-up after various bariatric procedures, bariatric surgery is the most effective treatment modality for morbidly obese patients in terms of total weight loss and and long-term weight maintenance. It has to be stressed however, that excellent bariatric results are fundamentally dependent on close inter-disciplinary team collaboration. This applies not only on patient´s pre-operative assessment, however even more on the life-long post-operative period, during which the patient should be looked after by physicians, surgeons, and other relevant obesity specialists.
The fundamentals of surgically induced energy malabsorption for the treatment of severe obesity Scopinaro Nicola 1 1 University of Genoa Medical School, Genoa, Italy There is energy malabsopriton when, contrary to what normally happens, part of the ingested calories are not absorbed. The existence of malabsorption can be revealed either by measuring the energy content or the fat content of the stools, or by measuring the energy intake and the energy expenditure: if the patients loses weight being his/her energy intake equal to or greater than the energy expenditure, or if the weight is stable being the energy intake greater than the energy expenditure, there is energy malabsorption. The firstly used type of malabsorption was that of the jejunoileal bypass (a shortening of the small bowel), which was indiscriminate and transitory. The type of malabsorption currently in use is that of biliopancreatic diversion (BPD, a diversion of bile and pancreatic secretion into the distal ileum that delays the meeting of food and biliopancreatic juices, thus causing a limited digestion), that is permanent and selective. In BPD there is a maximum absorption capacity for fat and starch an thus energy, consequently, all the energy intake exceeding that absorption threshold is not absorbed, and therefore, since the usual daily energy intake of the operated patient is largely higher that that threshold, daily energy absorption is constant for each subject. The consequent weight loss is then unavoidable, and the weight of stabilization is independent of the preoperative weight. Moreover, since the energy absorption is constant and independent of the energy intake, the weight of stabilization is also maintained indefinitely independently of the energy intake. Two extremely interesting specific effects of this type of malabsorption are the lifelong normalization of serum glucose and serum cholesterol in all operated subjects, without any medication and on totally free diet. There are some negative effects of malabsorption, essentially consisting of the reduced absorption of iron and calcium, with the consequent risk of anemia and bone demineralization), the increased loss of endogenous nitrogen, with the consequent risk of protein malnutrition, and the increased colonic fermentation and putrefaction phenomena, with the almost unavoidable side effects of bloating, flatulence and foul smelling stools. The characteristics of BPD malabsorption are such that it cannot be added to gastric restriction or vice versa. The combination of the two mechanisms would result in an anatomofunctional situation where only one mechanism is active, while the negative effects of both are present.
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